* XOMA Ltd. of Berkeley, California has announced the initiation of a phase I/II clinical study of anti-CD11a in kidney transplant recipients. A recombinant, humanized monoclonal antibody designed to selectively inhibit immune system T cells, anti-CD11a will be studied in combination with standard immunosuppressive drugs to test its safety and to determine if it further reduces graft rejection. A phase III trial of anti-CD11a in patients with plaque psoriasis began in December.
* Isotechnika Inc. of Edmonton, Canada, has filed an IND with the Food and Drug Administration to obtain permission to begin human clinical trials in the United States with ISAtx247, a candidate immunosuppressive drug. A similar filing in Canada was approved in March, and the company hopes to begin testing in both countries this spring. ISAtx247 is Isotechnika's first drug to complete preclinical testing. The company described it as a novel immunosuppressive drug designed for the prevention of organ rejection after transplantation and for the treatment of autoimmune diseases such as arthritis and psoriasis.
For Your Information:
Please be aware that medical advice, diagnoses and physician references cannot be obtained from this site.